Kyocera Introduces One-Action-Lock FPC/FFC Connectors
New products bring 2x improvement in foreign matter removal performance KYOTO, Japan--(BUSINESS WIRE)--Kyocera Corporation (President:…
3 years ago
Wire Stories
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
-Therapeutic equivalence and safety confirmed between DMB-3115 and Stelara in global phase III SEOUL, South…
3 years ago
Intuit Launches New QuickBooks Workforce Mobile App
New streamlined features help employees track work hours and pay all in one place MOUNTAIN…
3 years ago
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics
Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter’s High Sensitivity, High…
3 years ago
Global Industrial Gases Market to Reach $161.8 Billion by 2030: Growing Need for Surgical and Respiratory Applications Fuels the Sector – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Industrial Gases Market Size, Share, and Growth Analysis by Product Type, Distribution…
3 years ago
VMware Explore 2023—the Center of the Multi-Cloud Universe—to Feature Multiple Keynotes, Technology Innovation Showcase, Hands on Labs, and Much More
PALO ALTO, Calif.--(BUSINESS WIRE)--VMware, Inc. (NYSE: VMW) today announced highlights of the VMware Explore 2023…
3 years ago
Fisker Announces Fisker Extreme Vigyan Limited Edition for India Market
Fisker will produce 100 Fisker Extreme Vigyan Edition all-electric SUVs for the India market. Fisker…
3 years ago
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the…
3 years ago
Securian Canada Selects the FINEOS Platform to Expand Disability Management Offering
ATLANTA--(BUSINESS WIRE)--#digitaltransformation--FINEOS Corporation (ASX:FCL) announced today that Securian Canada has selected FINEOS for its disability…
3 years ago
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancer HANGZHOU,…
3 years ago